Improve PAD PERformance With METformin

Summary

The PERMET trial will determine whether metformin daily for six months improves six-minute walk performance in individuals with peripheral artery disease compared to placebo.

Timeline

Start

2017-05-23

Primary completion

2025-08-20

Completion

2025-11-01

Publications

• Results McDermott MM, Domanchuk KJ, Tian L, Zhao L, Zhang D, Bazzano L, Berceli S, Criqui MH, Ferrucci L, Guralnik JM, Leeuwenburgh C, Ho KJ, Ismaeel A, Kibbe MR, Korcarz C, Kosmac K, Lloyd-Jones D, Peterson CA, Stein JH, Sufit R, Wilkins J, Polonsky TS. Metformin to Improve Walking Performance in Lower Extremity Peripheral Artery Disease: The PERMET Randomized Clinical Trial. JAMA. 2026 Feb 3;335(5):407-415. doi: 10.1001/jama.2025.21358.
• McDermott MM, Cetlin MD, Domanchuk KJ, Xu S, Whipple MO, Polonsky T, Criqui MH, Guralnik JM, Tian L, Zhao L, Ho KJ, Greenland P, Treat-Jacobson D. Community-based recruitment with ankle brachial index testing to identify peripheral artery disease participants for randomized clinical trials. Am Heart J. 2026 Apr 24;300:107450. doi: 10.1016/j.ahj.2026.107450. Online ahead of print.
• Nayak P, Polonsky T, Tian L, Greenland P, Xu S, Zhang D, Zhao L, Criqui MH, Kibbe MR, Gladders B, Goodney P, Ho K, Guralnik JM, McDermott MM. Medical therapies, comorbid conditions, and functional performance in people with peripheral artery disease enrolled in clinical trials between 2004 and 2021. Vasc Med. 2023 Apr;28(2):144-146. doi: 10.1177/1358863X221145533. Epub 2023 Jan 1.

Drugs

Indications